1. HBV markers in haemodialysis Brazilian patients: a prospective 12-month follow-up.
- Author
-
Moreira RC, Deguti MM, Lemos MF, Saraceni CP, Oba IT, Spina AM, Nascimento-Lima AS, Fares J, Azevedo RS, Gomes-Gouvêa MS, Carrilho FJ, and Pinho JR
- Subjects
- Biomarkers blood, Brazil epidemiology, DNA, Viral blood, Epidemiologic Methods, Hepatitis B epidemiology, Hepatitis B etiology, Humans, Polymerase Chain Reaction, Hepatitis B diagnosis, Hepatitis B Antibodies blood, Hepatitis B Surface Antigens blood, Hepatitis B virus genetics, Hepatitis B virus immunology, Renal Dialysis
- Abstract
The aim of this study was to determine the prevalence and the incidence of hepatitis B virus (HBV) among haemodialysis (HD) subjects and to evaluate whether testing for serological markers at the time of admission is suitable for HBV screening in this population. One hundred twenty-three patients belonging to two HD centres from São Paulo, Brazil, were tested prospectively. HBV DNA was detected by polymerase chain reaction (PCR) in each of the prospective subjects (n = 123) during one year. Additionally, all samples (n = 1,476) were analysed for HBV serological markers. The prevalence of hepatitis B core antibody (anti-HBc), hepatitis B surface antigen (HBsAg) and HBV DNA were 34.1%, 15.4% and 8.1%, respectively, while the incidence was null. Fluctuation in HBV serology was observed in one patient. Only 37.8% (17/45) of cases responded to the HBV vaccine. Our results suggest that employing more than one HBV marker and repeated follow-up evaluations may improve HBV screening in HD units.
- Published
- 2010
- Full Text
- View/download PDF